

Lanreotide CLARINET

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects




Other adjustments



Lanreotide CLARINET

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Endocrine Tumours
 Therapeutic Indication: Grade 1 and a subset of grade 2 (Ki67 index up to 10%)
 GEP-NETs of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease
 Experimental Arm: Lanreotide
 Control Arm: Placebo



